iShares Biotechnology ETF (NASDAQ:IBB) Shares Sold by Pacific Capital Wealth Advisors Inc.

Pacific Capital Wealth Advisors Inc. cut its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 17.6% in the fourth quarter, HoldingsChannel reports. The firm owned 52,248 shares of the financial services provider’s stock after selling 11,136 shares during the quarter. iShares Biotechnology ETF makes up about 1.2% of Pacific Capital Wealth Advisors Inc.’s investment portfolio, making the stock its 15th biggest position. Pacific Capital Wealth Advisors Inc.’s holdings in iShares Biotechnology ETF were worth $6,908,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IBB. SPC Financial Inc. lifted its position in shares of iShares Biotechnology ETF by 2.4% during the 3rd quarter. SPC Financial Inc. now owns 3,265 shares of the financial services provider’s stock worth $475,000 after purchasing an additional 75 shares during the last quarter. Werba Rubin Papier Wealth Management raised its stake in iShares Biotechnology ETF by 2.7% in the third quarter. Werba Rubin Papier Wealth Management now owns 2,918 shares of the financial services provider’s stock valued at $425,000 after buying an additional 76 shares in the last quarter. Capital Investment Advisors LLC lifted its holdings in iShares Biotechnology ETF by 1.0% during the 4th quarter. Capital Investment Advisors LLC now owns 10,449 shares of the financial services provider’s stock worth $1,381,000 after buying an additional 99 shares during the last quarter. Magnus Financial Group LLC lifted its holdings in iShares Biotechnology ETF by 0.8% during the 4th quarter. Magnus Financial Group LLC now owns 12,967 shares of the financial services provider’s stock worth $1,714,000 after buying an additional 104 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its position in shares of iShares Biotechnology ETF by 12.0% during the 3rd quarter. Daiwa Securities Group Inc. now owns 1,028 shares of the financial services provider’s stock worth $150,000 after acquiring an additional 110 shares in the last quarter. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Price Performance

Shares of NASDAQ IBB opened at $138.37 on Tuesday. The stock’s 50-day simple moving average is $136.15 and its 200-day simple moving average is $141.77. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The business also recently disclosed a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were given a dividend of $0.0624 per share. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.